DE60119742D1 - Methode zur behandlung der hyperaktiven blase - Google Patents

Methode zur behandlung der hyperaktiven blase

Info

Publication number
DE60119742D1
DE60119742D1 DE60119742T DE60119742T DE60119742D1 DE 60119742 D1 DE60119742 D1 DE 60119742D1 DE 60119742 T DE60119742 T DE 60119742T DE 60119742 T DE60119742 T DE 60119742T DE 60119742 D1 DE60119742 D1 DE 60119742D1
Authority
DE
Germany
Prior art keywords
treatment
hyperactive
bubble
compound
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60119742T
Other languages
English (en)
Other versions
DE60119742T2 (de
Inventor
Russell A Bialecki
William Rumsey
Keith Russell
Wilmingt Bernstein
David Aharony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60119742D1 publication Critical patent/DE60119742D1/de
Publication of DE60119742T2 publication Critical patent/DE60119742T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60119742T 2000-06-22 2001-06-20 Methode zur behandlung der hyperaktiven blase Expired - Fee Related DE60119742T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0015246.2A GB0015246D0 (en) 2000-06-22 2000-06-22 Method for the treatment of urinary incontinence
GB0015246 2000-06-22
PCT/SE2001/001420 WO2001097811A1 (en) 2000-06-22 2001-06-20 Method for the treatment of overactive bladder

Publications (2)

Publication Number Publication Date
DE60119742D1 true DE60119742D1 (de) 2006-06-22
DE60119742T2 DE60119742T2 (de) 2007-05-31

Family

ID=9894138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119742T Expired - Fee Related DE60119742T2 (de) 2000-06-22 2001-06-20 Methode zur behandlung der hyperaktiven blase

Country Status (9)

Country Link
US (1) US20030139433A1 (de)
EP (1) EP1307202B1 (de)
JP (1) JP2003535901A (de)
AT (1) ATE326223T1 (de)
AU (1) AU2001274786A1 (de)
DE (1) DE60119742T2 (de)
ES (1) ES2262654T3 (de)
GB (1) GB0015246D0 (de)
WO (1) WO2001097811A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
SE0103795D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP2158910A1 (de) * 2003-10-27 2010-03-03 Novartis Ag Verwendung von Neurokinin-Antagonisten bei der Behandlung von Harnstoffinkontinenz
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AU2018282104A1 (en) * 2017-06-06 2019-12-12 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
US6365602B1 (en) * 1998-07-10 2002-04-02 Astra Zeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds

Also Published As

Publication number Publication date
GB0015246D0 (en) 2000-08-16
AU2001274786A1 (en) 2002-01-02
EP1307202B1 (de) 2006-05-17
US20030139433A1 (en) 2003-07-24
JP2003535901A (ja) 2003-12-02
DE60119742T2 (de) 2007-05-31
ATE326223T1 (de) 2006-06-15
WO2001097811A1 (en) 2001-12-27
EP1307202A1 (de) 2003-05-07
ES2262654T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
CY1110798T1 (el) Συνδυασμοι περιλαμβανοντες αντιμουσκαρινικους παραγοντες και αναστολεις pde4
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0215158A (pt) Derivados de pirrolidina e piperidina como antagonistas de nk1
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE224884T1 (de) Muscarin-antagonisten
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
DE60119742D1 (de) Methode zur behandlung der hyperaktiven blase
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
BR0213832A (pt) Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma
SE0100873D0 (sv) Method of treatment
BR0213776A (pt) Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma
DE60130677D1 (de) 1-(2-m-methansulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
WO2002067866A3 (en) Piperazine derivatives as metalloprotease inhibitors
DE60113704D1 (de) Verwendung einer kombination von nicotinsäuren oder deren derivaten und riboflavin zur herstellung eines arzneimittels zur behandlung von primären kopfschmerzen
TH101946B (th) Treatment of urinary incontinence

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee